Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes

Diabetic Medicine

Volumn 23, Issue 7, 2006, Pages 743-749

  Roach, P ^a   Malone, J K ^b  

^a INDIANA UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Glargine; Insulin analogues; Lispro; Postprandial glucose; Standardized test meal

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; FATTY ACID; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; MEGLITINIDE; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TEST MEAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EATING; FATTY ACIDS, NONESTERIFIED; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 33748549978     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01895.x     Document Type: Article

References (17)

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28 (Suppl. 1): S4-36.
2. Harris JA, Benedict FG. Biometric Studies of Basal Metabolism in Men, Publication 270. Washington, DC: Carnegie Institution of Washington 1919.
3. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972; 28: 577-584.
4. Taulbee J. A note on the use of nonparametric methods in the statistical analysis of the two-period changeover design. Biometrics 1982; 38: 1053-1055.
5. Nagelkerke N, Hart A, Oosting J. The two period binary response cross-over trial. Biom J 1986; 28: 863-869.
6. Service FJ, O'Brien PC, Rizza RA. Measurements of glucose control. Diabetes Care 1987; 10: 225-237.
7. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034-2044.
8. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005; 22: 374-381.
9. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P et al. Initiating insulin therapy in Type 2 diabetes: a comparison of biphasic and basal insulin analoguess. Diabetes Care 2005; 28: 260-265.
10. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259.
11. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycaemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23: 639-643.
12. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130-1136.
13. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636.
14. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
16. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
17. American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001; 24: 775-778.